Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ADITEC

Financiado

Cerrado

Advanced Immunization Technologies

Vaccines so far have been developed mostly by following an empiric approach. To prevent and possibly cure unresolved and emerging infectious diseases we need to fully exploit the potential of the human immune system. Progress in s... ver más

30/09/2017

TLS-S

41M€

Presupuesto del proyecto: 41M€

Líder del proyecto

Toscana Life Sciences Sviluppo No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Ver 37 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2017-09-30 No tenemos la información de la convocatoria

0% 73% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

37 Participantes

TLS-S

0.00€ | Lider

KINGS COLLEGE LONDON

N.D. | Participante

CNRS

N.D. | Participante

NVGH

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2017-88089-R VACUNAS FRENTE A ENFERMEDADES HUMANAS PREVALENTES Y SU OPTIM... 333K€ Cerrado

EAVI2020 European AIDS Vaccine Initiative 2020 24M€ Cerrado

SAF2013-45232-R VACUNAS FRENTE A ENFERMEDADES HUMANAS PREVALENTES Y OPTIMIZA... 593K€ Cerrado

SOLVE Sustainable COVID-19 Vaccination for Long-term Vaccine Immun... 9M€ Cerrado

PTQ2021-011651 Estudio sistemático de los mecanismos celulares implicados e... 70K€ Cerrado

ROCSI Romanian Centre of Excellence for Systems Immunology 400K€ Cerrado

Líder del proyecto

Toscana Life Sciences Sviluppo No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 41M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Vaccines so far have been developed mostly by following an empiric approach. To prevent and possibly cure unresolved and emerging infectious diseases we need to fully exploit the potential of the human immune system. Progress in science and technology makes it possible to achieve what was previously deemed impossible. The scope of this project is to produce knowledge necessary to develop novel and powerful immunization technologies for the next generation of human vaccines. This goal requires a multidisciplinary approach in which diverse but complementary scientific disciplines and technologies converge. Therefore some of the most competitive European research groups from public institutions and biotechs have agreed to join forces in ADITEC, together with top US groups on systems biology and adjuvants to support this enterprise. A systems biology approach will be used to study licensed and experimental vaccines in patient characterization studies and in clinical trials, to investigate the effect of adjuvants, vectors, formulations, delivery devices, routes of immunization, homologous and heterologous prime–boost schedules, as well as the impact of host factors such as age, gender, genetics and pathologies. Animal models will be used to complement human studies, and to select novel immunization technologies to be advanced to the clinic. To address these issues in a coordinated manner, ADITEC is organised on a matrix structure in which research themes and experimental approaches feed into each other. Training curricula will be created to impact on the formation of the next generation of EU researchers in the field. ADITEC scientists and institutions are part of the Sclavo Vaccines Association (SVA), which is dedicated to vaccines and vaccine research. SVA, acting as the coordinating institution, guarantees the long-term commitment and sustainability of this initiative, beyond the duration of ADITEC itself.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores